Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial - Université de Lorraine Access content directly
Journal Articles Kidney360 Year : 2023

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial

Abstract

Background: SGLT2 inhibitors, originally developed as glucose-lowering agents for treatment of type 2 diabetes, have been shown to have cardio-and kidney protective effects among chronic kidney disease (CKD) patients with and without diabetes. However, the mechanisms remain largely unknown. Methods: DECODE-CKD is an investigator-initiated, prospective, single-center, randomized, placebocontrolled trial evaluating the effects of 6 months of treatment with 10 mg of dapagliflozin compared with placebo on cardiac structure and function in 222 adults with CKD. The primary objective is to assess whether dapagliflozin improves LV mass index. Secondary and exploratory endpoints include changes in cardiac-and kidney markers, quality of life, depressive symptoms, and cognitive function. Conclusion: This is the first study to address the effects of SGLT2 inhibitors on cardiac structure and function in patients with CKD. The results will provide valuable insights into the mechanisms underlying the cardioprotective benefits of SGLT2 inhibitors in patients with CKD.
Fichier principal
Vignette du fichier
Effects_of_Dapagliflozin_on_EChOcardiographic.8.pdf (230.54 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY - Attribution

Dates and versions

hal-04025795 , version 1 (13-03-2023)

Licence

Attribution

Identifiers

Cite

Katja Vu Bartholdy, Niklas Dyrby Johansen, Nino Landler, Kristoffer Grundtvig Skaarup, Jesper Jensen, et al.. Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial. Kidney360, 2023, 4 (2), pp.143-149. ⟨10.34067/KID.0006982022⟩. ⟨hal-04025795⟩
21 View
27 Download

Altmetric

Share

Gmail Facebook X LinkedIn More